Concurrent Evaluation of p53, b-catenin, and a-Fetoprotein Expression in Human Hepatocellular Carcinoma

  • Torbenson, MD M
  • Kannangai, MD R
  • Abraham, MD S
  • et al.
N/ACitations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Recent models suggest that hepatocellular carcinoma (HCC) develops through several independent pathways marked by key mutations in the β-catenin or p53 gene. An additional pathway potentially is marked by aberrant expression of a-fetoprotein (AFP). To see whether these potential markers are expressed independently, we immunostained sequential sections from 55 HCCs. Of the cases, 30 (55%) were positive for 1 or more proteins: AFP, 19 cases (35%); p53, 12 cases (22%); and β-catenin, 9 cases (16%). Seven tumors (13%) were positive for more than 1 protein, with 4 of 7 positive in the same area of tumor and 3 of 7 positive in different areas of the carcinomas. By statistical analysis, expression of the markers was independent of one another and of tumor size. Concurrent evaluation of p53, β-catenin, and AFP protein expression showed no associations, supporting models in which these proteins might serve as markers of independent pathways in the development of HCC.

Cite

CITATION STYLE

APA

Torbenson, MD, M., Kannangai, MD, R., Abraham, MD, S., Sahin, MD, PhD, F., Choti, MD, M., & Wand, PhD, MD, J. (2004). Concurrent Evaluation of p53, b-catenin, and a-Fetoprotein Expression in Human Hepatocellular Carcinoma. American Journal of Clinical Pathology, 122(3), 377–382. https://doi.org/10.1309/yh0h-3fky-m4rm-u1jf

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free